Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis

Figure 5

Forest plots of comparison groups (Groups G-M). (a) The OR of rash for all grades checked using the random effect (RE) model in Group G (PD-1 or PD-L1 plus CTLA-4 versus PD-1 or PD-L1): subgroup analyses were carried out according to the types of immune checkpoint inhibitors (PD-1 or PD-L1). (b) The OR of rash for all grades checked using the random effect (RE) model in Group G (PD-1 or PD-L1 plus CTLA-4 versus PD-1 or PD-L1): subgroup analyses were carried out based on tumor type. (c) The OR of rash for all grades checked using the random effect (RE) model in Group G (PD-1 or PD-L1 plus CTLA-4 versus PD-1 or PD-L1): subgroup analyses were carried out according to the treatment lines (first or second line). (d) The OR of rash for all grades checked using the random effect (RE) model in Group H (PD-1 or PD-L1 versus CTLA-4). (e) The odds ratio of rash for all grades calculated by the random effect (RE) model in Group H (PD-1 or PD-L1 versus CTLA-4): subgroup analyses were carried out according to the treatment lines (first or second line). (f) The OR of rash for all-grade checked using the random effect (RE) model in Group I (PD-1 or PD-L1 plus CTLA-4 versus Chemotherapy): subgroup analyses were carried out based on tumor type. (g) The OR of rash for all grades checked using the random effect (RE) model in Group J (PD-1 or PD-L1 plus CTLA-4 plus Chemotherapy versus Chemotherapy): subgroup analyses were carried out based on treatment regimens. (h) The OR of rash for all grades checked using the random effect (RE) model in Group K (PD-1 or PD-L1 plus Bevacizumab versus Sorafenib): subgroup analyses were carried out according to the types of immune checkpoint inhibitors (PD-1 or PD-L1). (i) The odds ratio of rash for all-grade checked using the random effect (RE) model in Group L (PD-1 or PD-L1 plus CTLA-4 versus CTLA-4). (j) The odds ratio of rash for all grades checked using the random effect (RE) model in Group M (PD-1 or PD-L1 versus Methotrexate/docetaxel/cetuximab).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)